Biosimilar Development insights

  1. Preparing For The Future - Visions And Insights For Biomanufacturing

    In this e-book, you’ll find insight and advice from some of the industry’s top experts about current trends in biomanufacturing, modern process intensification techniques and the outlook for digital automation.  We’ll explore innovative process approaches that can be applied at various scales and stages of development in hopes of providing you with a visionary guide of how to effectively manufacture your molecule.

  2. Nunc Roller Bottles Excel With ST, Vero, And MDBK Cells Application Note

    A third-party study was conducted to compare the performance of Thermo Scientific™ Nunc™ Roller Bottles (1.2 and 2.5X) and 850 cm2 roller bottles from another supplier, for the culturing of ST, Vero, and MDBK cells.

  3. Rapid, Serum-Free, High-Yield Antibody Production In Nunc PETG Roller Bottles Application Note

    A rapid, flexible, and high-yield approach both hybridoma expansion and for antibody production using a serum-free medium in Nunc PETG Roller Bottles.

  4. Nunc Cell Factory System Extractable Review

    How product design influences biopharmaceutical manufacturer extractable profiles.

  5. Master Cell Bank Production Of Liver Carcinoma Cells

    Improved productivity using a Nunc High Density Cell Factory 52-layer system.

  6. Culture Of Human Mesenchymal Stem Cells In Nunc Cell Factory Systems

    Helpful methodology that can be applied to the large-scale expansion of other cell types for use in various applications using Cell Factory systems.

  7. BioProcess Containers – Materials Of Construction

    This paper details some of the important characteristics of the plastic films used to manufacture BPCs, with a discussion on E&L and Thermo Fisher Scientific’s strategy for characterizing the extractables profiles of our BPC films.

  8. Are Today’s Processes Efficient Enough For The Future Of Vaccine And Viral Vector Production?

    By recognizing the limitations of today’s production processes, the industry may be able to overcome the challenges, complexity, and high cost of manufacturing vaccines and viral vector-based therapies.

  9. Is Your Biologic At Risk For Protein Aggregation? Part 3

    The main culprit of a failing biologic drug is usually a flawed formulation. In this article, we cover formulation components and how they may affect protein aggregation.  Part three of a three-part series.

  10. Is Your Biologic At Risk For Protein Aggregation?

    How to prevent protein aggregation via considerations for the manufacturing process and container selection criteria. Part two of a three-part series.